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ABSTRACT
Introduction Exercise intolerance is common in patients 
with chronic obstructive pulmonary disease (COPD) and, 
although multifactorial, it is largely caused by lower- limb 
muscle dysfunction. Research has shown that patients 
with severe to very severe COPD have significantly lower 
levels of muscle carnosine, which acts as a pH buffer 
and antioxidant. Beta- alanine (BA) supplementation has 
been shown to consistently elevate muscle carnosine 
in a variety of populations and may therefore improve 
exercise tolerance and lower- limb muscle function. The 
primary objective of the current studies is to assess the 
beneficial effects of BA supplementation in enhancing 
exercise tolerance on top of two types of exercise 
training (non- linear periodised exercise (NLPE) training or 
neuromuscular electrical stimulation (NMES)) in patients 
with COPD.
Methods and analysis Two randomised, double- blind, 
placebo- controlled trials have been designed. Patients will 
routinely receive either NLPE (BASE- TRAIN trial) or NMES 
(BASE- ELECTRIC trial) as part of standard exercise- based 
care during their 8- to-10 week pulmonary rehabilitation 
(PR) programme. A total of 222 patients with COPD (2×77 
= 154 patients in the BASE- TRAIN trial and 2×34 = 68 
patients in the BASE- ELECTRIC trial) will be recruited 
from two specialised PR centres in The Netherlands. For 
study purposes, patients will receive 3.2 g of oral BA 
supplementation or placebo per day. Exercise tolerance 
is the primary outcome, which will be assessed using the 
endurance shuttle walk test (BASE- TRAIN) or the constant 
work rate cycle test (BASE- ELECTRIC). Furthermore, 
quadriceps muscle strength and endurance, cognitive 
function, carnosine levels (in muscle), BA levels (in blood 
and muscle), markers of oxidative stress and inflammation 
(in blood, muscles and lungs), physical activity and quality 
of life will be measured.
Ethics and dissemination Both trials were approved 
by CMO Regio Arnhem- Nijmegen, The Netherlands 
(NL70781.091.19. and NL68757.091.19).
Trial registration number NTR8427 (BASE- TRAIN) and 
NTR8419 (BASE- ELECTRIC).
INTRODUCTION
Exercise intolerance is one of the key 
disabling factors in patients with chronic 
obstructive pulmonary disease (COPD). 
Although complex and multifactorial, exer-
cise intolerance is largely caused by lower- limb 
Strengths and limitations of this study
 ► Two prospective, randomised, double- blind, 
placebo- controlled trials are designed and will be 
performed in two specialised pulmonary rehabil-
itation centres to assess the effects of oral beta- 
alanine (BA) supplementation on exercise tolerance 
and muscle carnosine in patients with chronic ob-
structive pulmonary disease (COPD).
 ► These are the first studies in which BA supplemen-
tation will be combined with a supervised exercise 
intervention (non- linear periodised exercise or neu-
romuscular electrical stimulation as part of pulmo-
nary rehabilitation) in patients with COPD.
 ► In- depth assessment of outcomes enables to iden-
tify relevant factors that explain variances in muscle 
carnosine loading and to analyse carnosine’s role in 
skeletal muscle dysfunction in COPD.
 ► Long- term benefits will not be investigated as limit-
ed funding makes it difficult to set up a comprehen-
sive follow- up period in these trials.
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muscle dysfunction.1 Structural and metabolic muscular 
alterations in patients with COPD lead to a decreased 
muscle oxidative capacity, which results in early lactate 
acidosis and contractile fatigue.2 To date, non- linear 
periodised exercise (NLPE) training and neuromus-
cular electrical stimulation (NMES; for the most disabled 
and dyspnoeic patients) are among the best available 
strategies to improve exercise tolerance and lower- limb 
muscle function in COPD.3 Indeed, muscle strength and 
endurance improved following 8–12 weeks of exercise 
training. Improved muscle function was accompanied by 
increased exercise tolerance, a better quality of life and 
less symptoms, without a change in lung function.4–6 Even 
though exercise- based interventions, such as NLPE and 
NMES, significantly improve exercise tolerance in COPD, 
targeted nutritional modulation should also be consid-
ered as a potential ergogenic aid to further enhance their 
efficacy.7
Beta- alanine (BA), a naturally occurring beta amino 
acid, is a specific nutritional supplement that is mostly 
used by athletes to increase exercise tolerance.8 Once 
ingested, BA combines with histidine to form carnosine, 
one of the most abundant metabolites in human muscle 
cells.9 Carnosine’s main physiological roles in skeletal 
muscle include its function as a pH buffer and calcium 
regulator. High concentrations of muscle carnosine 
appear to delay the onset of contractile fatigue, as 
carnosine is able to bind muscle hydrogen ions during 
intense exercise, thereby moderating the decline in intra-
cellular pH10 and to increase calcium sensitivity in muscle 
fibres.11 Moreover, carnosine can serve as an antioxi-
dant by directly interacting with reactive oxygen species 
(ROS).12 13
The muscle homeostasis and contractile function of 
especially fast- twitch fibres seem to depend on the pres-
ence of carnosine, since they contain twice as much 
carnosine as slow- twitch fibres.14 It is well known that the 
proportion of fast- twitch fibres in the quadriceps muscle 
of patients with COPD is increased in those with more 
advanced airflow limitation compared with patients with 
less severe airflow limitation.15 Therefore, patients with 
severe COPD intuitively are expected to have the highest 
muscle carnosine concentrations. Interestingly, patients 
with a severe degree of airflow limitation had lower muscle 
carnosine levels compared with healthy controls.16 This 
carnosine deficiency may be closely related to exercise- 
induced oxidative stress in the lower- limb muscles of 
patients with COPD1 or with the fact that in these muscle- 
wasted COPD patients fast- twitch fibre size is significantly 
decreased.17
Oral supplementation of BA, the rate- limiting factor 
for carnosine synthesis in skeletal muscle, is reported 
to be safe18 and can increase muscle carnosine levels by 
60%–80% in both healthy young adults19 and elderly,20 21 
without exercise training. However, research has shown 
that trained muscles load carnosine even more efficiently 
than untrained muscles.22 Hence, it is very plausible to 
hypothesise that BA supplementation in patients with 
COPD receiving either NLPE or NMES training (as part 
of pulmonary rehabilitation (PR)) will increase muscle 
carnosine levels, which, in turn, will result in a positive 
effect on exercise tolerance and lower- limb muscle func-
tion, by buffering pH,23 24 and scavenging ROS.12 13 These 
adaptations may translate into improved functional 
capacity during activities of daily living and improved 
quality of life.
The primary targets of both exercise training and 
BA supplementation are the muscles of ambulation. 
Nevertheless, it seems reasonable to hypothesise that 
an enhanced bioavailability of carnosine in the body, by 
means of BA supplementation, may have an antioxida-
tive effect in both the lungs and the brain. Interestingly, 
on oral supplementation, carnosine is taken up by the 
PEPT2 transporter at the lung membrane, resulting in 
enhanced carnosine levels in lung tissue.25 26 Likewise, 
elevations in carnosine in all compartments of the brain 
were measured after BA supplementation in rats.27 These 
elevations in carnosine increased the resiliency to stress 
and were inversely associated with anxiety index.
To date, the safety and efficacy of BA supplementa-
tion during usual care (not combined with exercise 
training) in patients with COPD has only been assessed 
once (NCT02770417). Therefore, we have designed two 
randomised, double- blind, placebo- controlled trials in 
which we will assess the beneficial effects of BA supplemen-
tation in enhancing exercise tolerance in addition to two 
types of exercise training (NLPE and NMES) in patients 
with COPD. This manuscript describes the protocol of 
the BASE- TRAIN (NLPE) and BASE- ELECTRIC (NMES) 
study and gives an overview of its strengths, methodolog-
ical considerations and assumed clinical implications.
METHODS AND ANALYSIS
The BASE- TRAIN study and BASE- ELECTRIC study are 
designed by the BASES consortium, a multidisciplinary 
collaboration between CIRO (Horn, The Netherlands), 
Radboud University Medical Centre Dekkerswald 
(Nijmegen, The Netherlands), MEREM (Hilversum, 
The Netherlands), Maastricht University Medical 
Centre (Maastricht, The Netherlands), Hasselt Univer-
sity (Diepenbeek, Belgium), Ghent University (Ghent, 
Belgium) and Montpellier University (Montpellier, 
France). The consortium consists of researchers from 
organisations with years of experience in various related 
disciplines. To provide valuable insight from the patient 
perspective, a patient advisory board, consisting of repre-
sentatives of both the CIRO client council and Lung 
Foundation Netherlands, is closely involved by advising 
and monitoring the BASES consortium.
Study design
Two prospective, randomised, double- blind, placebo- 
controlled trials enrolling patients with COPD with 
explicit functional limitations and high symptom burden 
(GOLD classification B or D) have been designed and 
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will be performed in Radboud University Medical Centre 
Dekkerswald (Nijmegen, The Netherlands) and CIRO 
(Horn, The Netherlands). The expected trial duration is 
2 years from first patient in (1 September 2020) to last 
patient out (1 September 2022). In both trials, the inter-
vention (BA supplementation) will be part of a compre-
hensive, interdisciplinary PR programme consisting of 
educational sessions, psychosocial and nutritional coun-
selling, supervised physical exercise training, occupa-
tional therapy and COPD exacerbation management, as 
defined in the latest statement by the American Thoracic 
Society (ATS) and the European Respiratory Society 
(ERS).3
Eligible patients are those who satisfy the criteria listed 
in table 1. Patients are excluded if they meet at least 
one of the following criteria: unstable cardiac disease, 
use of anabolic steroids during PR programme, history 
of drugs/alcohol abuse, participants treated with NMES 
(BASE- TRAIN trial) or NLPE (BASE- ELECTRIC trial) 
during the PR programme, vegetarianism,28 inability to 
understand the Dutch language, self- reported BA supple-
mentation in the past 3 months (wash- out period: 9 
weeks),29 participation in a PR programme within the past 
12 months, inability to perform an incremental shuttle 
walk test (BASE- TRAIN trial) or cardiopulmonary exer-
cise test (BASE- ELECTRIC trial). Furthermore, patients 
with bleeding disorder, a recent trauma of the muscle or 
an infection in the region of the proposed biopsy will be 
excluded for the muscle biopsies.30
The regular PR programme at the PR centres consists 
of a baseline assessment, followed by the (BASE- TRAIN: 
inpatient or outpatient; BASE- ELECTRIC: inpatient) PR 
programme and is ended with a post- rehabilitation assess-
ment. After completion of the baseline assessment and 
obtaining informed consent, an additional study- related 
appointment is scheduled with included patients approxi-
mately 1 week prior to the start of the PR programme. The 
appointment includes fasting venous blood sampling, a 
vastus lateralis muscle biopsy (optional, not required), 
two cognitive function tests (modified Wisconsin Card 
Sorting Test; M- WCST and Stroop Colour- Word Test; 
SCWT) and, only in the BASE- ELECTRIC trial, two 
tests for lung inflammatory biomarkers (volatile organic 
compounds; VOCs and fractional nitric oxide concentra-
tion in exhaled breath; FeNO). This additional testing 
day will be repeated after the rehabilitation period. The 
total study duration per subject will be 10–12 weeks. A flow 
chart is included to give an overview of the study design 
and the main procedures that subjects will undergo in the 
course of both trials (figure 1: BASE- TRAIN trial; figure 2: 
BASE- ELECTRIC trial).
Intervention
Study participants will be randomly assigned to either 
3.2 g of sustained release BA (SR CarnoSyn) or identical 
looking placebo supplementation (both produced by 
Natural Alternatives International, San Marcos, USA) for 
a duration of 8–10 weeks. Patients, researchers and all PR 
staff, except the researchers performing randomisation 
and distributing the study supplements, will be blinded to 
treatment allocation.
The intervention will start directly from the onset (day 
1) of the regular PR programme and will end after the 
last measurement of the study. Participants are instructed 
to coingest the supplements with meals, as this can bene-
ficially influence muscle carnosine loading.31 As part of 
standard care, the total protein intake during the reha-
bilitation period will be set at 1.5–1.9 g of protein per 
kilogram of fat- free mass per day32 for all patients and a 
protein- rich supplement (±20 g of protein) is provided to 
every patient directly after training sessions. During break-
fast and lunch, 2 tablets of BA/placebo (2×0.8 g) will be 
taken each time, resulting in a total daily intake of 3.2 g of 
BA/placebo. Furthermore, the participants will receive a 
personal diary, in which they keep track of intake of tablets 
and any possible side effects. With subjects’ self- reported 
compliance on tablet intake (diary) and returning of the 
pill containers, compliance with the intervention will be 
assessed. In addition, a moment will be scheduled every 
week in the context of patient safety to discuss possible 
side effects with the patient. The investigators will report 
all serious adverse events (SAEs) without undue delay 
after obtaining knowledge of the events to the sponsor, 
Table 1 Overview of the inclusion criteria for the two randomised controlled trials
Inclusion criteria BASE- TRAIN trial BASE- ELECTRIC trial
Exercise modality NLPE NMES
Age 40–80 years 40–80 years
mMRC dyspnoea grade ≥2 ≥3
No exacerbation/hospitalisation <4 weeks <4 weeks
Endurance time* Not specified 100–300 s
Quadriceps strength Not applicable <80% predicted
PR programme Inpatient+Outpatient Inpatient
*Endurance time is measured as walking endurance time (BASE- TRAIN) or cycle endurance time (BASE- ELECTRIC).
mMRC, modified Medical Research Council; NLPE, non- linear periodised exercise; NMES, neuromuscular electrical stimulation; PR, 
pulmonary rehabilitation; s, seconds.
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who will report the SAEs to the accredited METC (CMO 
Regio Arnhem- Nijmegen).
Training protocols
In the BASE- TRAIN trial, NLPE training is applied to 
the patients. Periodisation is an essential organisational 
strategy and a cardinal principal of exercise training.5 33 34 
Periodisation involves a division in distinct and smaller, 
more easy manageable but interrelated phases.34 The 
goals of these distinct phases contribute to the overall 
training plan. NLPE is featured by a frequent manip-
ulation of training intensity, duration and repetition- 
volume. Exercise protocols are ultimately adapted based 
Figure 1 Timeline for the BASE- TRAIN trial, in which all measurements, inclusion criteria, moment of randomisation and 
supplementation period are outlined. AE, acute exacerbations; BA, beta- alanine; COPD, chronic obstructive pulmonary disease; 
ESWT, endurance shuttle walk test; FV, flow volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, 
modified Medical Research Council; NLPE, non- linear periodised exercise training; PL, placebo; PR, pulmonary rehabilitation.
Figure 2 Timeline for the BASE- ELECTRIC trial, in which all measurements, inclusion criteria, moment of randomisation and 
supplementation period are outlined. AE, acute exacerbations; BA, beta- alanine; CET, cycle endurance time; COPD, chronic 
obstructive pulmonary disease; CWRT, constant work rate cycle test; FV, flow volume; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; mMRC, modified Medical Research Council; NMES, neuromuscular electrical stimulation; PL, 
placebo; PR, pulmonary rehabilitation; QMS, quadriceps muscle strength.
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on information emerging from the training sessions (eg, 
dyspnoea, residual fatigue, percutaneous oxygen desatu-
ration, exertion of heaviness, pain).34 The programme is 
started with a preplanned NLPE protocol in which the 
patients receive three training sessions of 1–1.5 hours 
per week. The training plan and division in phases is 
shown in the online supplement (online supplemental 
file 1). As mentioned, individual protocol adaptions are 
possible, based on patients’ responses during training 
(e.g. cause of exercise intolerance, response to a partic-
ular protocol). Whole- body exercise and resistance 
training are combined in each training session, and 
training parameters as frequency, intensity, duration 
and number of repetitions are monitored. The endur-
ance training will be performed on a treadmill and the 
strength training will primary be performed on the leg 
press (lower extremity) and chest press and pull down 
(upper extremity). Furthermore, category- ratio Borg 
scores of leg fatigue and dyspnoea are reported immedi-
ately following exercise completion to evaluate exercise- 
induced breathlessness and fatigue.35
In the BASE- ELECTRIC trial, NMES, being the primary 
exercise modality, is applied to the patients. During 
NMES, quadriceps and calf muscles of both legs will be 
simultaneously stimulated with a portable battery‐oper-
ated electrical stimulator, using eight carbon‐rubber 
electrodes (Tensmed S84, Enraf‐Nonius, Rotterdam, The 
Netherlands).36 The stimulation protocol will consist 
of a symmetrical biphasic square pulse at 75 Hz (high- 
frequency NMES), a total duty cycle of 16 s and a pulse 
time of 400 μs during a directly supervised session lasting 
21 min in total. This high- frequency NMES has shown 
before to be safe, feasible and efficacious in dyspnoeic and 
weakened patients with COPD.6 37 Patients will be specif-
ically encouraged to increase current intensity at their 
will according to tolerance in each training session. The 
contraction time will be 6 s with 8 s relaxation excluding 
1 s ramp‐up and 1 s ramp‐down. A total of eight carbon‐
rubber electrodes in moistened sponges are placed on 
the target muscles (four electrodes on each leg): two pairs 
of 8×12 cm on the quadriceps muscles and two pairs of 
4×6 cm on the calf muscles. The electrodes on the quad-
riceps muscles are placed transversally 5–10 cm distal to 
the inguinal fold and 4–8 cm proximal to the patella. The 
electrodes on the calf muscles are placed longitudinally 
on the belly of the gastrocnemii muscles (protocol in 
accordance with study NL30153.068.09/MEC 09-3-0726).
Study procedure
Patients will be informed about the trials by their treating 
chest physician during the evaluation of their baseline 
assessment. If patients are eligible and show interest 
in the study, they will receive the patient information 
letter. Participation will be verified through a phone 
call at least 1 week later. At the start of the study- related 
appointment, written informed consent will be obtained 
and participants will be randomised to either the experi-
mental or the placebo group using a web- based generated 
randomisation programme. Randomisation will be strat-
ified for gender28 38 in both trials and for one or two 
baseline endurance shuttle walk tests (ESWT) in the 
BASE- TRAIN trial. This will be explained in more detail 
in the Primary outcome section.
Participants will be randomised in a 1:1 ratio to BA (SR 
Carnosyn) or placebo. Allocation to treatment will be 
concealed. Randomisation and allocation (sealed opaque 
envelopes) will be performed by independent researchers 
not related to the current studies. These persons are 
neither participating in clinical treatment nor processing 
the study data. At the start of their PR programme, 
participants will receive a container with the interven-
tion supplements. The containers will be provided with a 
blinded label, ensuring that the researchers, the PR staff 
and the participant will not be able to see which inter-
vention supplement is taken. After inclusion, the partic-
ipant’s general practitioner and chest physician will be 
informed about study participation.
Outcomes
Primary outcome
The primary outcome in both studies is exercise tolerance, 
a functional outcome that is measured as walking endur-
ance time (BASE- TRAIN trial) or cycle endurance time 
(BASE- ELECTRIC trial).
Walking endurance will be assessed via the ESWT, a 
standardised externally controlled constant paced field 
test at 85% of the predetermined maximal velocity (eval-
uated by the incremental shuttle walk test (ISWT)) until 
exhaustion.39 The preferred ESWT duration in this study 
is below 10 min, which has multiple reasons. First of all, 
this allows enough room for an additional improvement 
due to BA supplementation on pulmonary rehabilitation 
(MID: 174–279 s).40 Second, because of the hyperbolic 
power–duration relationship of the constant- load test, the 
interindividual preintervention ESWT time should be as 
much homogeneous as possible to better interpret inter-
vention efficacy.41 42 At last, BA supplementation is proven 
to be most effective in exercise durations between 0.5 
and 10 min.43 Therefore, patients with an ESWT >10 min 
perform the ESWT again at a higher speed.
Cycle endurance time will be determined with the 
constant work- rate cycle test (CWRT), performed on 
an ergometer at 75% of the maximal work rate (Wmax; 
determined by a cardiopulmonary exercise test (CPET) 
performed on a separate day during assessment) to voli-
tional exhaustion (with a maximum of 20 min).44
Secondary outcomes
Besides the CPET (both trials) and the ISWT (only in the 
BASE- TRAIN trial) is the exercise capacity measured with 
the 6 min walking test (6MWT) in the BASE- ELECTRIC 
trial and will be performed twice at baseline.45 Isometric 
and isokinetic quadriceps strength and endurance will 
be assessed using a computerised dynamometer (Biodex 
System 4 Pro, Biodex Medical Systems, New York, USA). 
Isometric quadriceps strength will be determined by three 
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maximal unilateral isometric knee extensions for 5 s at a 
knee angle of 60o, interspersed with 15 s of rest and will 
be defined as highest peak torque (newton- metre, Nm). 
Furthermore, participants will perform 30 sequential 
volitional maximal contractions at an angular velocity of 
90o per second, while seated upright and the hip joint in 
90o of flexion. Isokinetic quadriceps muscle strength will 
be defined as the highest peak torque (Nm). The isoki-
netic quadriceps muscle endurance will be defined as the 
total amount of delivered work (joules) during the set of 
30 repetitions.46 Maximal dynamic isotonic strength, to 
determine maximal quadriceps strength (leg press), will 
be assessed by one- repetition maximum using standard 
(fitness) equipment.47
Body composition is measured by bioelectrical imped-
ance analysis48 (BASE- TRAIN trial) or dual- energy X- ray 
absorptiometry49 (BASE- ELECTRIC trial). Physical 
activity will be measured using activity monitors (BASE- 
TRAIN: MoveMonitor; BASE- ELECTRIC: Actigraph 
GT9X), which provide simple, valid and reliable measures 
of physical activity in patients with COPD.50 The Short 
Physical Performance Battery test is designed to measure 
functional status and physical performance51 and will be 
carried out in the BASE- ELECTRIC trial.
Vastus lateralis muscle biopsies will be performed by an 
experienced physician during two study- related appoint-
ments (pre- rehabilition, at least 1 week before the start 
of the PR programme; and post- rehabilitation) using 
standard aseptic technique and local anaesthesia. A side 
cutting needle muscle biopsy will be passed through 
an incision to obtain approximately 100 mg of muscle 
tissue.52 53 Muscle components of carnosine metabolism 
(eg, BA, carnosine, taurine and histidine) will be quanti-
fied by means of reserved- phase high- performance liquid 
chromatography.54 Muscle oxidative stress and inflam-
mation will be assessed via immunoblotting and specific 
activity kits.55 56 Fasting venous blood will be assessed for 
the analysis of systemic components of carnosine metab-
olism as well as systematic markers of oxidative stress and 
inflammation at rest.
Two domains of cognitive function57 will be evaluated: 
executive functioning will be assessed using the M- WCST 
and divided attention will be examined via the SCWT.58 59 
Lung inflammatory and oxidative stress biomarkers will 
be measured (only in the BASE- ELECTRIC trial) using 
VOCs60 and FeNO.61
The severity of dyspnoea is measured via the modified 
Medical Research Council dyspnoea scale.62 Health- 
related quality of life will be assessed using the COPD 
Assessment Test.63 The Hospital Anxiety and Depression 
Scale will be used as a screening tool to detect clinical 
signs of anxiety and depression.64 65 Fatigue severity will 
be measured by the subjective fatigue subscale of the 
Checklist Individual Strength (CIS- Fatigue).66 Problem-
atic activities of daily life will be measured (only in BASE- 
ELECTRIC study) using the Canadian Occupational 
Performance Measure.67 At last, the subjects’ compliance 
on tablet intake, patient safety and possible side effects 
are assessed as secondary outcome measures as described 
in the Intervention section.
Other outcomes
Additional outcomes are used to characterise patients at 
baseline. Pulmonary function will be assessed using post- 
bronchodilator spirometry, whole- body plethysmography 
and diffusion capacity according to the ATS/ERS guide-
lines for pulmonary function testing.68–70 Furthermore, 
respiratory muscle strength, using maximal inspiratory 
pressure and maximal expiratory pressure measure-
ments, will be determined.71 An arterial blood sample is 
collected to determine arterial blood gases at rest.72 Addi-
tionally, patient characteristics as age, gender, level of 
education, marital status, smoking status, exacerbation/
hospitalisation frequency and medical history (Charlson 
Comorbidity Index),73 medication and/or oxygen use 
will be assessed at baseline during an intake interview.
Table 2 provides an overview of the measurements 
performed during the several time points of the studies.
Sample size calculation
Since no preliminary data are available concerning the 
effects of BA supplementation combined with exercise 
training on exercise tolerance (walking or cycle endur-
ance time) in an elderly population (with or without 
chronic disease), a more conservative approach based 
on the minimal clinical important differences (MCID) of 
the walking and cycle endurance time, in COPD patients 
treated in PR, is used.
In the BASE- TRAIN trial, a total of 154 patients is 
needed to detect a MCID of 177 s40 74 in walking endur-
ance time with an estimated drop- out rate of 10%, based 
on recent local unpublished data (α=0.05; β=0.80).
In the BASE- ELECTRIC trial, a total of 68 patients is 
needed to detect a MCID of 105 s75 in cycle endurance 
time with an estimated dropout rate of 25%, based on the 
study of Sillen et al (α=0.05; β=0.90).6
Furthermore, a sample size calculation for the required 
muscle biopsies is included. Based on the unpublished 
findings of De Brandt et al (NCT02770417; effect size: 
1.39), a group size of n=15 is required for each group in 
each trial, including an estimated dropout rate of 25% 
(α=0.05; β=0.90). Therefore, the aim will be to perform 
muscle biopsies in 30 patients with COPD (15 for the BA 
group and 15 for the placebo group) in each trial.
Data management and statistical analyses
In order to minimise missing data, only essential infor-
mation will be collected at each visit, user- friendly case- 
report forms have been developed, and the majority of 
the tests and questionnaires will be performed in the 
presence of a researcher. The study variables will be 
tested for normality. For all data, point measures and 
measures of variability will be provided. Demographic 
variables (such as age, sex, educational level, smoking 
history) will be compared between patients in the BA and 
placebo group, using unpaired t- test or Mann- Whitney U 
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Table 2 Overview outcome measurements
Baseline 
assessment
Additional study 
appointment 1
PR 
programme
Post- PR 
assessment
Additional study 
appointment 2
Patient characteristics
  Demographics, including age, gender, marital status X       
  Medical history: Charlson Comorbidity Index X       
  COPD history: number of exacerbations and 
hospital admissions
X       
  Smoking history and behaviour X       
  Current medication X       
  Use of long- term oxygen therapy X       
Safety reporting
  Exacerbations    X    
  Hospitalisations    X    
  Side effects    X    
Exercise capacity and exercise tolerance
  Cardiopulmonary exercise test X       
  Constant work rate cycle test X    X   
  Incremental shuttle walk test X*       
  Endurance shuttle walk test X*    X*   
  6 min walk test X†    X†   
Body composition
  Body mass index X    X   
  Bioelectrical impedance analysis X*    X*   
  Dual- energy X- ray absorptiometry scan X†    X†   
Muscle function
  Quadriceps muscle strength (computerised 
dynamometer)
X    X   
  Quadriceps muscle endurance (computerised 
dynamometer)
X    X   
  One- repetition maximum X    X   
Muscle characteristics (muscle biopsy)
  Components of carnosine metabolism  X   X
  Muscle inflammation  X   X
  Muscle oxidative stress  X   X
Pulmonary function
  Spirometry/flow volume X    X   
  Whole- body plethysmography X       
  Diffusion capacity X       
  Maximal inspiratory and expiratory pressure X    X   
  Arterial blood gases, including PaO2 and PaCO2 X       
Systemic factors
  Systemic components of carnosine metabolism  X   X
  Systemic markers of oxidative stress  X   X
  Systemic markers of inflammation  X   X
Physical activity
  MoveMonitor/Actigraph measurement X    X   
Questionnaires
  Dyspnoea: Modified Medical Research Council X    X   
  Health- related quality of life: COPD Assessment Test X    X   
Continued
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test, as appropriate, for continuous variables and χ2 tests 
for categorical variables.
To evaluate the changes in exercise tolerance, lower- 
limb muscle function, muscle carnosine, muscle and 
systemic BA, taurine and histidine, muscle, systemic 
and pulmonary markers for inflammation and oxidative 
stress and cognitive function, a 2×2 general linear model 
repeated measures analysis of variance (ANOVA) will be 
performed, with ‘supplementation group’ (BA, PL) as 
between- subjects factor and ‘time’ (PRE vs POST) as a 
within- subjects factor. If, however, the assumptions of 
repeated measures ANOVA are not met, POST–PRE 
deltas (∆) will be calculated, and exercise tolerance 
changes between groups will be analysed using an 
unpaired t- test (non- parametrical alternative: Mann- 
Whitney U test). Differences in changes (∆) in quality 
of life, dyspnoea, symptoms of anxiety and depression, 
problematic activities of daily life and fatigue between 
groups will be analysed using an unpaired t- test when 
the data are normally distributed. For skewed data, the 
Mann- Whitney U test will be performed. Pearson’s or 
Spearman’s correlation will be calculated between base-
line muscle carnosine content and absolute increase in 
muscle BA/carnosine. Furthermore, correlations will 
be conducted between relative changes in muscle BA/
carnosine content and performance parameters. To 
counteract the problem of multiple comparisons, the 
Bonferroni correction will be used. All statistical anal-
yses will be performed using Statistical Package for the 
Social Sciences (SPSS) v. 25.0. A priori, a two- tailed p 
value of ≤0.05 is considered as significant.
Patient and public involvement
Members of the CIRO client council and patient repre-
sentatives from Lung Foundation Netherlands are 
active members of the BASES consortium and have been 
involved in setting up the grant proposal, in reviewing 
both study designs (particularly the patient informed 
consent) before submission for ethical approval and 
in discussing the outcomes assessment. Moreover, this 
patient advisory board will provide unprecedented 
insight into improving study feasibility, recruitment and 
retention, and in understanding patient perceptions 
and receptivity to current approaches, new practices 
and possible future (combinations of) therapies. The 
patient advisory board will also be included in the devel-
opment of post- trial communication.
Ethics and dissemination
The studies will be conducted according to the 
guidelines of the Declaration of Helsinki (64th 
WMA General Assembly, Fortaleza, Brazil, October 
2013)76 and in accordance with the Medical Research 
Involving Human Subjects Act (WMO). Written 
informed consent will be obtained from all partici-
pants before participation. Both trials were approved 
by CMO Regio Arnhem- Nijmegen, The Netherlands 
(NL70781.091.19. and NL68757.091.19) and are regis-
tered at https://www. trialregister. nl/. The results will 
be submitted for publication in peer- reviewed journals 
and will be presented at (inter)national conferences. 
If desired, participants will be informed about the 
results of the studies.
Baseline 
assessment
Additional study 
appointment 1
PR 
programme
Post- PR 
assessment
Additional study 
appointment 2
  Mood status: Hospital Anxiety and Depression scale X    X   
  Fatigue: Checklist Individual Strength (CIS- Fatigue) X    X   
  Evaluation muscle biopsy: feedback form  X   X
  Canadian Occupational Performance Measurement 
(COPM)
X†    X†   
Functional mobility
  Short Physical Performance Battery X†    X†   
Cognitive function
  Modified Wisconsin Card Sorting Test  X   X
  Stroop Colour- Word Test\  X   X
Lung inflammation and oxidative stress
  Volatile organic compounds measurement  X†   X†
  Fractional exhaled nitric oxide measurement  X†   X†
Compliance
  Patient diary      X
  Counting remaining tablets      X
*Exclusively performed in BASE- TRAIN trial.
†Exclusively performed in BASE- ELECTRIC trial.
Table 2 Continued
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DISCUSSION
Strengths
To date, most studies that examined the effects of BA 
supplementation have focused on improving exercise 
tolerance in athletes.14 24 77 However, results of BA 
supplementation in the elderly population suggest that 
there is rationale for further research in this area.20 21 78 
To the best of our knowledge, our planned studies will 
be the first in which BA supplementation is combined 
with a supervised exercise intervention in patients with 
COPD. A major strength of the present studies is the fact 
that these are methodologically rigorous randomised 
controlled trials using a computer- generated randomi-
sation scheme and strict allocation concealment with 
accurate sample size calculation. This will provide a 
valid indication of the effectiveness of BA supplemen-
tation in patients with COPD receiving PR. In addition, 
the use of a responsive outcome measure for exercise 
tolerance will increase the likelihood of being able 
to assess whether there are any benefits in adding BA 
supplementation to PR in patients with COPD. In the 
current studies, we specifically focus on patients with 
COPD with explicit functional limitations and high 
symptom burden attending PR. The strict inclusion 
criteria are another strength of both trials, as patients 
with severe COPD are expected to benefit the most 
from BA supplementation.
Furthermore, we optimised both the dosage and the 
duration of supplementation in order to increase the 
muscle carnosine response to BA supplementation.79 
In addition, 3.2 g of BA per day for a duration of 8–10 
weeks will result in a cumulative dose of 179–224 g of 
BA, which will lead to significantly augmented muscle 
carnosine concentrations (>40%).80 The protocols also 
embody other factors that can lead to greater muscle 
carnosine gains, such as supplement formulation (slow- 
release formula), ingestion timing in relation to meals 
(coingestion with breakfast and lunch) and exercise 
(NLPE or NMES training programme as part of PR).79 
Moreover, the trials examine the mechanism of carnosine 
loading in a diseased population by analysing levels of 
carnosine and related dipeptides in blood samples and 
biopsy samples of the vastus lateralis muscle. This way, we 
aim to identify relevant factors that explain variances in 
muscle carnosine loading and try to elucidate carnosine’s 
role as a potential antioxidant. And last, the structure of 
the BASES consortium, including a patient advisory board, 
a core project team and a steering committee, allows us 
to enhance the research capacity, to share (academic) 
resources, to disseminate study results and to accelerate 
future research.
Methodological considerations
First, limited funding makes it difficult to set up long- 
term follow- up, although analysing the sustainability of 
outcomes would certainly be worthwhile. As such, long- 
term benefits will not be investigated. Second, despite 
our efforts to increase compliance through inpatient 
follow- up during the PR programme, adherence to the 
prescribed supplementation protocol is only monitored 
by asking participants about their intake using a diary and 
by documenting the remaining tablets at the end of the 
supplementation period. Therefore, it is possible that the 
actual compliance is different and forgotten tablets are 
discarded. However, this is comparable with daily practice 
as patients may behave in the same manner. Furthermore, 
the actual efficacy of BA supplementation is monitored 
by means of quantifying muscle carnosine levels through 
muscle biopsies of the vastus lateralis muscle.
Third, all patients start with a preplanned NLPE 
protocol in the BASE- TRAIN trial. However, individual 
protocol adaptions are possible based on patients’ 
responses during training as it is part of usual care. This 
might result in (minor) differences in exercise training 
programme between the BA and placebo group. As we 
deliver patient- tailored care with the purpose to generate 
an optimal result for each patient, which depends on 
the patient’s abilities, needs and goals and is therefore 
patient- specific, we will not be able to apply one single 
protocol to all patients. Moreover, training parameters 
as frequency, intensity, duration and number of repeti-
tions will be closely monitored during the study. This will 
allow additional post hoc analyses to evaluate the effect of 
potential differences in exercise training programme that 
arise throughout the study. Furthermore, we acknowledge 
the fact that the protein- rich supplement, given after each 
training session as part of standard care, could poten-
tially reduce the between- group difference regarding the 
primary outcome (exercise tolerance), since additional 
protein intake could enhance training benefits in the 
control group. In this way, however, the potential risk of 
a BA- induced decline in circulating and/or muscle histi-
dine levels81 is minimised by additional intake of protein 
(post- training) in these patients with COPD.
Clinical implications
The BASE- TRAIN and BASE- ELECTRIC studies will 
examine whether and to what extent BA supplementa-
tion can augment the exercise tolerance outcomes of 
PR. Improving exercise tolerance is a major therapeutic 
goal in COPD and there are theoretical reasons for 
presuming that specific oral nutritional supplements may 
further enhance the outcomes of exercise training, an 
intervention that is of proven clinical benefit in patients 
with COPD.1 3 Furthermore, the present studies will gain 
insight in the characteristics of patients that do and do 
not benefit from BA supplementation and whether 
these benefits directly mirror changes in intracellular 
carnosine.
CONCLUSION
In conclusion, both exercise training and BA supplemen-
tation effectively increase exercise tolerance in several 
populations. The BASE- TRAIN and BASE- ELECTRIC 
trials will be the first to evaluate the effects of BA 
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supplementation in addition to exercise training (either 
NLPE or NMES) in patients with COPD. In this article, the 
study rationale and protocols of both trials are described, 
and a preliminary analysis of the possible strengths and 
limitations is outlined.
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